CAT has three in-house clinical programs that remain unpartnered and outside the AstraZeneca deal. CAT has also 11 existing discovery programs
that AZN has rights to opt into and jointly develop.

Product Indication Status Partner

Trabio lerdelimumab Scarring following glaucoma surgery Ph III
CAT-213 bertilimumab Allergic rhinitis Ph II
CAT-354 MAb against IL-13 Asthma Ph I

Humira adalimumab Rheumatoid arthritis (RA) Mkt Abbott
Humira adalimumab Juvenile RA Ph III Abbott
Humira adalimumab Crohn’s disease Ph III Abbott
Humira adalimumab Psoriatic arthritis Ph III Abbott
Humira adalimumab Ankylosing spondylitis Ph III Abbott
Humira adalimumab Chronic plaque psoriasis Ph II Abbott
ABT-874 (J695) MAb against IL-12 Autoimmune diseases Ph II Abbott

CAT-192 metelimumab Diffuse systemic sclerosis Ph II Genzyme
GC-1008 MAb against TGF beta Idiopathic pulmonary fibrosis Preclin Genzyme

Lympho Stat-B Systemic lupus erythematosus Ph II Human Genome
Lympho Stat-B RA Ph II Human Genome
HGS-ETR1 Non-Hodgkin’s lumphoma Ph II Human Genome
HGS-ETRI Colorectal cancer Ph II Human Genome
HGS-ETR2 Solid tumors Ph I Human Genome
ABthrax Anthrax Ph I Human Genome

MYO-029 Muscular dystrophy & age-related sacropenia Ph I Wyeth